Search
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalto endogenous insulin, and in the long term, damage to pancreatic islet cells. … , resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.
Insulin glulisine
go.drugbank.com/drugs/DB01309Approvedto produce or synthesize the insulin needed to manage circulating blood sugar levels. … Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.
Abatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigationalAbatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human … The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.
Categories: Selective T Cell Costimulation ModulatorTrifarotene
go.drugbank.com/drugs/DB12808ApprovedInvestigational[A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects … to vitamin A and are analogous only in function.
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma … [A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients
Products: TEXATE-T, NORDIMET 10MG ILO I E FERPegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigationalIt is used following surgical resection of the primary tumor to detect areas of remaining cancer. … [L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigationalThe HER2 oncoprotein, the product of the human _ERBB2_/mouse _neu_ genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). … However, due to its modified Fc region, margetuximab binds with higher affinity to both CD16A variants and exhibits weaker binding to the inhibitory CD32B Fc receptor, resulting in more efficient antibody-dependent
Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsOmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent … classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA. … Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome